Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy

Table 1 Baseline patient characteristics

Patient characteristic	n*	%*
Age, mean ± SD	67.9	± 11.2
Gender, female	31	68.9
Race
White	34	75.5
Black or African American	8	17.8
Other¹	3	6.7
Rheumatologic disease
Rheumatoid arthritis	22	48.9
Lupus	5	11.1
Polymyalgia rheumatica	4	8.9
Psoriatic arthritis	4	8.9
Other²	10	22.2
Malignancy type
Non-small cell lung cancer	22	48.9
Renal cell carcinoma	5	11.1
Melanoma	4	8.9
Other³	14	31
Comorbidities
Other autoimmune disease⁴	4	8.9
Prior malignancy	10	22.2
Hypothyroidism	16	35.6
Cardiovascular disease	13	28.9
Immune checkpoint inhibitor
Pembrolizumab	21	46.7
Nivolumab	16	35.6
Atezolizumab	5	11.1
Durvalumab	1	2.2
Ipilimumab	1	2.2
Nivolumab + pembrolizumab	1	2.2
Anti-rheumatic therapy at initiation of ICI	22	48.9
Hydroxychloroquine	11	24.4
DMARD⁵	4	8.9
JAK inhibitor⁶	1	2.2
Oral corticosteroid	3	4.4
Combination⁷	3	8.9
Autoimmune disease controlled before ICI therapy
Yes	40	88.9
No	5	11.1
Treatment line
1	19	42.2
2	17	37.8
3 or more	9	20.0

ICI, immune checkpoint inhibitor; DMARD, disease modifying anti-rheumatic drug; JAK, Janus kinase
*Unless otherwise specified
¹Other races include Asian (n = 1) and unknown (n = 2)
²Other rheumatologic disease include ankylosing spondylitis (n = 2), dermatomyositis (n = 1), limited scleroderma (n = 2), sarcoidosis (n = 2), Sjogren's syndrome (n = 2), and undifferentiated connective tissue disease (n = 1)
³Other malignancy types include bladder cancer (n = 1), breast cancer (n = 3), endometrial carcinoma (n = 2), merkel cell carcinoma (n = 1), small cell lung cancer (n = 3), squamous cell carcinoma of the skin (n = 1), squamous cell of the tongue (n = 1), poorly differentiated lung cancer (n = 2)
⁴Other autoimmune diseases include autoimmune hepatitis (n = 1), Grave’s disease (n = 2), and psoriasis (n = 1)
⁵DMARDS include methotrexate (n = 2), sulfasalazine (n = 1), leflunomide (n = 1)
⁶JAK inhibitor includes tofacitinib (n = 1)
⁷Combinations include methotrexate and etanercept, hydroxychloroquine and prednisone, and tacrolimus and prednisone (for heart transplant)

ISSN: 2520-1026